Somiari Richard I, Sullivan Anthony, Russell Stephen, Somiari Stella, Hu Hai, Jordan Rick, George Alisha, Katenhusen Richard, Buchowiecka Alicja, Arciero Cletus, Brzeski Henry, Hooke Jeff, Shriver Craig
Clinical Breast Care Project, Windber Research Institute, Windber PA 15963, USA.
Proteomics. 2003 Oct;3(10):1863-73. doi: 10.1002/pmic.200300560.
Large-scale proteomics will play a critical role in the rapid display, identification and validation of new protein targets, and elucidation of the underlying molecular events that are associated with disease development, progression and severity. However, because the proteome of most organisms are significantly more complex than the genome, the comprehensive analysis of protein expression changes will require an analytical effort beyond the capacity of standard laboratory equipment. We describe the first high-throughput proteomic analysis of human breast infiltrating ductal carcinoma (IDCA) using OCT (optimal cutting temperature) embedded biopsies, two-dimensional difference gel electrophoresis (2-D DIGE) technology and a fully automated spot handling workstation. Total proteins from four breast IDCAs (Stage I, IIA, IIB and IIIA) were individually compared to protein from non-neoplastic tissue obtained from a female donor with no personal or family history of breast cancer. We detected differences in protein abundance that ranged from 14.8% in stage I IDCA versus normal, to 30.6% in stage IIB IDCA versus normal. A total of 524 proteins that showed > or = three-fold difference in abundance between IDCA and normal tissue were picked, processed and identified by mass spectrometry. Out of the proteins picked, approximately 80% were unambiguously assigned identities by matrix-assisted laser desorbtion/ionization-time of flight mass spectrometry or liquid chromatography-tandem mass spectrometry in the first pass. Bioinformatics tools were also used to mine databases to determine if the identified proteins are involved in important pathways and/or interact with other proteins. Gelsolin, vinculin, lumican, alpha-1-antitrypsin, heat shock protein-60, cytokeratin-18, transferrin, enolase-1 and beta-actin, showed differential abundance between IDCA and normal tissue, but the trend was not consistent in all samples. Out of the proteins with database hits, only heat shock protein-70 (more abundant) and peroxiredoxin-2 (less abundant) displayed the same trend in all the IDCAs examined. This preliminary study demonstrates quantitative and qualitative differences in protein abundance between breast IDCAs and reveals 2-D DIGE portraits that may be a reflection of the histological and pathological status of breast IDCA.
大规模蛋白质组学将在新蛋白质靶点的快速展示、鉴定和验证以及阐明与疾病发生、发展和严重程度相关的潜在分子事件中发挥关键作用。然而,由于大多数生物体的蛋白质组比基因组复杂得多,蛋白质表达变化的全面分析需要超出标准实验室设备能力的分析工作。我们描述了首次使用OCT(最佳切割温度)包埋活检、二维差异凝胶电泳(2-D DIGE)技术和全自动斑点处理工作站对人乳腺浸润性导管癌(IDCA)进行的高通量蛋白质组学分析。将来自四个乳腺IDCA(I期、IIA期、IIB期和IIIA期)的总蛋白分别与从一名无乳腺癌个人或家族病史的女性供体获得的非肿瘤组织中的蛋白进行比较。我们检测到蛋白质丰度的差异范围从I期IDCA与正常组织相比的14.8%,到IIB期IDCA与正常组织相比的30.6%。总共挑选了524种在IDCA和正常组织之间丰度差异≥三倍的蛋白质,通过质谱进行处理和鉴定。在挑选出的蛋白质中,约80%在首次通过基质辅助激光解吸/电离飞行时间质谱或液相色谱-串联质谱时被明确鉴定。还使用生物信息学工具挖掘数据库,以确定鉴定出的蛋白质是否参与重要途径和/或与其他蛋白质相互作用。凝溶胶蛋白、纽蛋白、核纤层蛋白、α-1-抗胰蛋白酶、热休克蛋白-60、细胞角蛋白-18、转铁蛋白、烯醇化酶-1和β-肌动蛋白在IDCA和正常组织之间显示出丰度差异,但在所有样本中的趋势并不一致。在有数据库匹配结果的蛋白质中,只有热休克蛋白-70(丰度更高)和过氧化物酶体增殖物激活受体2(丰度更低)在所有检测的IDCA中显示出相同的趋势。这项初步研究证明了乳腺IDCA之间蛋白质丰度的定量和定性差异,并揭示了二维DIGE图谱,这可能反映了乳腺IDCA的组织学和病理学状态。